Eli Lilly and Company (NYSE:LLY) Shares Bought by Avalon Trust Co

Avalon Trust Co boosted its position in Eli Lilly and Company (NYSE:LLY) by 36.7% during the 4th quarter, HoldingsChannel reports. The firm owned 995 shares of the company’s stock after buying an additional 267 shares during the quarter. Avalon Trust Co’s holdings in Eli Lilly and Company were worth $580,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Lipe & Dalton acquired a new position in Eli Lilly and Company during the 4th quarter worth $26,000. Thompson Investment Management Inc. acquired a new stake in Eli Lilly and Company in the third quarter worth about $27,000. Legacy Financial Group LLC bought a new position in Eli Lilly and Company in the 3rd quarter valued at about $35,000. Optiver Holding B.V. acquired a new position in Eli Lilly and Company during the 3rd quarter valued at about $36,000. Finally, Family CFO Inc bought a new stake in shares of Eli Lilly and Company during the 3rd quarter worth about $40,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Down 2.8 %

Shares of LLY traded down $20.94 during trading hours on Friday, reaching $734.97. The company’s stock had a trading volume of 4,595,138 shares, compared to its average volume of 2,629,045. The company has a 50 day moving average of $761.06 and a two-hundred day moving average of $671.38. The company has a quick ratio of 0.73, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. The firm has a market cap of $698.52 billion, a price-to-earnings ratio of 108.24, a P/E/G ratio of 1.50 and a beta of 0.37. Eli Lilly and Company has a 1-year low of $419.80 and a 1-year high of $800.78.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Tuesday, April 30th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.05. The firm had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The company’s revenue for the quarter was up 26.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.62 EPS. As a group, research analysts predict that Eli Lilly and Company will post 13.83 EPS for the current fiscal year.

Analysts Set New Price Targets

LLY has been the subject of several recent analyst reports. DZ Bank cut shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective for the company. in a report on Wednesday, February 21st. Citigroup boosted their price objective on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research note on Tuesday, April 2nd. The Goldman Sachs Group raised their target price on Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research note on Thursday, April 11th. BMO Capital Markets boosted their price target on shares of Eli Lilly and Company from $900.00 to $1,001.00 and gave the stock an “outperform” rating in a research report on Wednesday. Finally, Barclays raised their price objective on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research report on Wednesday, February 7th. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $757.95.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.